Format

Send to

Choose Destination
Am J Hematol. 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871.

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.

PMID:
21069865
DOI:
10.1002/ajh.21871
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center